These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33753241)

  • 1. PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates.
    Sammour Y; Dezorzi C; Austin BA; Borkon AM; Everley MP; Fendler TJ; Khumri TM; Lawhorn SL; Nassif ME; Vodnala D; Magalski A; Kao AC; Sperry BW
    J Card Fail; 2021 Jul; 27(7):812-815. PubMed ID: 33753241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis.
    Jennings DL; Sultan L; Mingov J; Choe J; Latif F; Restaino S; Clerkin K; Habal MV; Colombo PC; Yuzefpulskaya M; Sayer G; Uriel N; Baker WL
    Heart Fail Rev; 2023 Jan; 28(1):149-156. PubMed ID: 35687219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation.
    LaFratte C; Peasah SK; Huang Y; Hall D; Patel U; Good CB
    J Am Heart Assoc; 2023 Sep; 12(18):e029707. PubMed ID: 37702065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
    J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 inhibitors in clinical practice: Novel directions and new experiences.
    Rallidis LS; Skoumas I; Liberopoulos EN; Vlachopoulos C; Kiouri E; Koutagiar I; Anastasiou G; Kosmas N; Elisaf MS; Tousoulis D; Iliodromitis E
    Hellenic J Cardiol; 2020; 61(4):241-245. PubMed ID: 31783124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.
    Donald DR; Reynolds VW; Hall N; DeClercq J; Choi L
    J Clin Lipidol; 2022; 16(3):315-324. PubMed ID: 35367164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks.
    Hollstein T; Kassner U; Grenkowitz T; Schumann F; Bobbert T; Steinhagen-Thiessen E
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):83-92. PubMed ID: 32514867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
    Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
    Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease.
    Itzhaki Ben Zadok O; Mager A; Leshem-Lev D; Lev E; Kornowski R; Eisen A
    Cardiovasc Drugs Ther; 2022 Feb; 36(1):85-92. PubMed ID: 33394363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
    Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
    Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.
    Laufs U; Birkenfeld AL; Fraass U; Hohenstein B; Siegert C; Klotsche J; Steinhagen-Thiessen E; Pittrow D; Dexl S; Salmen S; Schettler VJJ; Parhofer KG;
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):119-129. PubMed ID: 36178485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study.
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Corciulo C; Lo Surdo G; Biagini S; Sampietro T;
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):808-814. PubMed ID: 37773882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
    Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
    J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy.
    Warden BA; Minnier J; Watts GF; Fazio S; Shapiro MD
    J Clin Lipidol; 2019; 13(4):580-585. PubMed ID: 31130489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors.
    Blanchard V; Chemello K; Hollstein T; Hong-Fong CC; Schumann F; Grenkowitz T; Nativel B; Coassin S; Croyal M; Kassner U; Lamina C; Steinhagen-Thiessen E; Lambert G
    Cardiovasc Res; 2022 Jul; 118(9):2103-2111. PubMed ID: 34314498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.